pain therapy market

The Current State

A woman with a headache

The pain therapy market » Current state

Treatments lacking in a USD65 bn market

TREATMENT OF NEUROPATHIC PAIN is still a clearly unmet medical need. There are no pain medicines which have universal efficacy and most partially effective drugs have unwanted morphine-like side effects.

Neuropathic pain patients frequently suffer from associated anxiety and depression which exacerbates their pain and generates a vicious cycle of low mood and increasing pain.

The estimated direct and indirect healthcare costs for neuropathic pain disorders in the European Member States vary between 2 and 3% of GDP across the EU. In 2016, this estimate would result in a cost of up to 440 billion Euros. Developing an effective and safe treatment for neuropathic pain would both save the member states large costs and improve quality of life for their people.

If the DOR agonists are able to attenuate both pain and the associated affective disorders, assuming absence of toxicity and contraindications, they will have enormous market potential.

A new neuropathic pain medicine such as PN6047 would aid patients’ return to work, increase efficiency and reduce direct health service costs.

The US Opioid Crisis

Synthetic opioids other than Methadone
Natural and semisynthetic opioids

Since 1999 the amount of prescription opioids sold to pharmacies, hospitals, and doctors’ offices in the USA quadrupled with no overall change in the amount of pain that Americans reported.

Deaths from prescription μ-opioids  e.g. oxycodone, hydrocodone, morphine have also more than quadrupled since 1999.

Jan 2018; New York sued eight Pharma companies for fuelling the opioid crisis with conventional opioid medicines.

Latest news

View all
December 22, 2022

PharmNovo at Biostock

CEO Per von Mentzer presented PharmNovo at the BioStock - Connecting Innovation and Capital Life Science Fall Summit 2022. Watch his presentation addressing the large, unmet medical needs in the neuropathic pain market and learn more about our ongoing clinical trial and how we will achieve project milestones as PharmNovo moves forward.

Read more
December 22, 2022

Seasons Greetings 2022

The PharmNovo team would like to wish you a Merry Christmas and a Happy New Year!

Read more
October 11, 2022

Strengthening the team

PharmNovo has strengthened the team with a new experienced Project Manager and a Clinical Trial Manager

Read more
September 20, 2022

Good press in SvD

Read the story about PharmNovo and our drug candidate PN6047 for neurophatic pain and its ongoing phase I studies in Svenska Dagbladet.

Read more

By using this website, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.

Awesome 👌